Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-440 in Healthy and Chronic Hepatitis B Participants
NCT03439488Phase 1Completed
- Sponsor
- Alios BioPharma
- Start
- Mar 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial of JNJ-64530440 in Chronic Hepatitis B (CHB) (3 arms), sponsored by Alios BioPharma. Primary endpoints: Number of Participants With Adverse Events at 8 weeks, Number of Participants With Clinically Significant Changes in Physical Examination at 8 weeks and 5 more. Started Mar 2018; status: completed.
02
Drugs
JNJ-64530440
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03439488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03439488.